Associations of pulmonary microvascular blood volume with per cent emphysema and CT emphysema subtypes in the community: the MESA Lung study
- PMID: 39496494
- PMCID: PMC11999787
- DOI: 10.1136/thorax-2024-222002
Associations of pulmonary microvascular blood volume with per cent emphysema and CT emphysema subtypes in the community: the MESA Lung study
Abstract
Background: Pulmonary microvasculature alterations are implicated in emphysema pathogenesis, but the association between pulmonary microvascular blood volume (PMBV) and emphysema has not been directly assessed at scale, and prior studies have used non-specific measures of emphysema.
Methods: The Multi-Ethnic Study of Atherosclerosis Lung Study invited participants recruited from the community without renal impairment to undergo contrast-enhanced dual-energy CT. Pulmonary blood volume was calculated by material decomposition; PMBV was defined as blood volume in the peripheral 2 cm of the lung. Non-contrast CT was acquired to assess per cent emphysema and novel CT emphysema subtypes, which include the diffuse emphysema subtype and small-airways-related combined bronchitic-apical emphysema subtype. Generalised linear regression models included age, sex, race/ethnicity, body size, smoking, total lung volume and small airway count.
Results: Among 495 participants, 53% were never-smokers and the race/ethnic distribution was 35% white, 31% black, 15% Hispanic and 18% Asian. Mean PMBV was 352±120 mL; mean per cent emphysema was 4.95±4.75%. Lower PMBV was associated with greater per cent emphysema (-0.90% per 100 mL PMBV, 95% CI: -1.29 to -0.51). The association was of larger magnitude in participants with 10 or more pack-years smoking and airflow obstruction, but present among participants with no smoking history or airflow limitation, and was specific to the diffuse CT emphysema subtype (-1.48% per 100 mL PMBV, 95% CI: -2.31 to -0.55).
Conclusion: In this community-based study, lower PMBV was associated with greater per cent emphysema, including in participants without a smoking history or airflow limitation, and was specific to the diffuse CT emphysema subtype.
Keywords: Emphysema.
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: EAHo is a founder and shareholder of VIDA Diagnostics, which makes the software used for secondary per cent emphysema measures in this article. YS and NA report receiving grants from the NIH. JG is a shareholder of VIDA Diagnostics and reports receiving grants from the NIH. DWK acknowledges grant support from the US Department of Defense and ZOLL Medical Corporation for work unrelated to this study, is a co-founder and shareholder of OscillaVent, and is listed as a co-inventor on US and European patents related to multi-frequency oscillatory ventilation. Unrelated to this work, EDM reports consulting fees paid by Amgen, AstraZeneca, Boehringer Ingelheim, Edwards Lifescience, Esperion, Medtronic, Merck, Novo Nordisk, Novartis, New Amsterdam and Pfizer. Unrelated to this work, PN reports receiving grant funding from GE Healthcare, consulting fees from Cannon, honoraria from the Society of Cardiovascular CT and American Society of Nuclear Cardiology, as well as owning stock in Moderna. BS reports receiving grants from the NIH, Canadian Institutes of Health Research, Fonds de la recherche en santé du Québec and the Research Institute of the McGill University Health Centre. RGB reports receiving grants from the COPD Foundation, the US Environmental Protection Agency, the American Lung Association and the NIH.
Figures


Similar articles
-
CT Emphysema Subtypes and Cardiac Hemodynamics Estimated on MRI: The Multi-Ethnic Study of Atherosclerosis COPD Study.Chest. 2025 Aug;168(2):364-378. doi: 10.1016/j.chest.2025.03.009. Epub 2025 Mar 27. Chest. 2025. PMID: 40157599
-
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study.Eur Respir J. 2024 Dec 12;64(6):2400820. doi: 10.1183/13993003.00820-2024. Print 2024 Dec. Eur Respir J. 2024. PMID: 39362671 Free PMC article.
-
Proteomic discovery analysis of quantitatively assessed emphysema in the general population. The MESA Lung Study.Respir Res. 2025 Jul 4;26(1):236. doi: 10.1186/s12931-025-03312-8. Respir Res. 2025. PMID: 40616090 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Manual lymphatic drainage for lymphedema following breast cancer treatment.Cochrane Database Syst Rev. 2015 May 21;2015(5):CD003475. doi: 10.1002/14651858.CD003475.pub2. Cochrane Database Syst Rev. 2015. PMID: 25994425 Free PMC article.
Cited by
-
CT Emphysema Subtypes and Cardiac Hemodynamics Estimated on MRI: The Multi-Ethnic Study of Atherosclerosis COPD Study.Chest. 2025 Aug;168(2):364-378. doi: 10.1016/j.chest.2025.03.009. Epub 2025 Mar 27. Chest. 2025. PMID: 40157599
References
-
- Organization WH. Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. Geneva, 2020.
-
- Spain DM, Seigel H, Bradess VA. Emphysema in apparently healthy adults. JAMA 1973;224(3):322 – 25. - PubMed
Publication types
MeSH terms
Grants and funding
- 75N92020D00002/HL/NHLBI NIH HHS/United States
- 75N92020D00001/HL/NHLBI NIH HHS/United States
- R01 HL077612/HL/NHLBI NIH HHS/United States
- N01 HC095167/HL/NHLBI NIH HHS/United States
- R01 HL093081/HL/NHLBI NIH HHS/United States
- R01 HL121270/HL/NHLBI NIH HHS/United States
- R01 HL155816/HL/NHLBI NIH HHS/United States
- 75N92020D00004/HL/NHLBI NIH HHS/United States
- N01 HC095166/HL/NHLBI NIH HHS/United States
- N01 HC095160/HL/NHLBI NIH HHS/United States
- N01 HC095161/HL/NHLBI NIH HHS/United States
- 75N92020D00005/HL/NHLBI NIH HHS/United States
- N01 HC095168/HL/NHLBI NIH HHS/United States
- R01 HL071759/HL/NHLBI NIH HHS/United States
- N01 HC095169/HL/NHLBI NIH HHS/United States
- P30 ES005605/ES/NIEHS NIH HHS/United States
- N01 HC095159/HL/NHLBI NIH HHS/United States
- 75N92020D00003/HL/NHLBI NIH HHS/United States
- N01 HC095163/HL/NHLBI NIH HHS/United States
- 75N92020D00007/HL/NHLBI NIH HHS/United States
- N01 HC095162/HL/NHLBI NIH HHS/United States
- 75N92020D00006/HL/NHLBI NIH HHS/United States
- N01 HC095165/HL/NHLBI NIH HHS/United States
- N01 HC095164/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources